Royce & Associates LP increased its stake in shares of Aspen Aerogels Inc. (NYSE:ASPN) by 16.1% during the second quarter, Holdings Channel reports. The institutional investor owned 113,752 shares of the company’s stock after buying an additional 15,756 shares during the period. Royce & Associates LP owned about 0.55% of Aspen Aerogels worth $565,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ASPN. Goldman Sachs Group Inc. acquired a new stake in shares of Aspen Aerogels during the first quarter worth approximately $115,000. Balter Liquid Alternatives LLC boosted its stake in shares of Aspen Aerogels by 162.8% in the first quarter. Balter Liquid Alternatives LLC now owns 33,236 shares of the company’s stock worth $150,000 after buying an additional 20,590 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Aspen Aerogels by 71.6% in the second quarter. GSA Capital Partners LLP now owns 44,129 shares of the company’s stock worth $219,000 after buying an additional 18,419 shares during the last quarter. Palisade Capital Management LLC NJ acquired a new stake in shares of Aspen Aerogels during the first quarter worth approximately $221,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Aspen Aerogels during the first quarter worth approximately $371,000. Institutional investors own 76.10% of the company’s stock.

Aspen Aerogels Inc. (NYSE:ASPN) traded up 0.3851% on Wednesday, reaching $5.2401. 42,644 shares of the company traded hands. Aspen Aerogels Inc. has a 12 month low of $3.38 and a 12 month high of $8.87. The company’s market capitalization is $107.85 million. The company has a 50-day moving average price of $4.88 and a 200-day moving average price of $4.60.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. Aspen Aerogels had a negative net margin of 3.14% and a negative return on equity of 3.35%. The business earned $27.70 million during the quarter, compared to analyst estimates of $30.99 million. During the same period in the previous year, the business posted ($0.12) EPS. Equities research analysts expect that Aspen Aerogels Inc. will post ($0.30) EPS for the current year.

A number of brokerages have recently commented on ASPN. Craig Hallum began coverage on shares of Aspen Aerogels in a report on Tuesday. They issued a “buy” rating and a $10.00 target price for the company. JPMorgan Chase & Co. reduced their target price on shares of Aspen Aerogels from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Friday, August 5th. Canaccord Genuity reaffirmed a “buy” rating and issued a $8.50 target price on shares of Aspen Aerogels in a report on Thursday, August 4th. Zacks Investment Research raised shares of Aspen Aerogels from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Finally, Citigroup Inc. reduced their target price on shares of Aspen Aerogels from $6.50 to $6.00 and set a “buy” rating for the company in a report on Thursday, July 7th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.70.

In other news, Director William P. Noglows bought 20,000 shares of Aspen Aerogels stock in a transaction on Wednesday, August 24th. The stock was purchased at an average cost of $4.98 per share, with a total value of $99,600.00. Following the purchase, the director now directly owns 46,178 shares of the company’s stock, valued at approximately $229,966.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mark L. Noetzel bought 13,576 shares of Aspen Aerogels stock in a transaction on Tuesday, August 9th. The shares were purchased at an average cost of $4.74 per share, with a total value of $64,350.24. Following the completion of the purchase, the director now directly owns 36,178 shares in the company, valued at $171,483.72. The disclosure for this purchase can be found here. 14.70% of the stock is currently owned by insiders.

About Aspen Aerogels

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Want to see what other hedge funds are holding ASPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aspen Aerogels Inc. (NYSE:ASPN).

Receive News & Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.